Clinical trials: Lung Tumors
Small-cell Lung Cancer, Small Cell Lung Carcinoma
A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer
The purpose of this study is to test the safety of a new medication, Olaparib, combined with radiation therapy for participants with small cell lung cancer.
- Trial name
- NCT03532880
- Testing
- Olaparib Pill 50 mg, Olaparib Pill 100 mg, Olaparib Pill 150 mg
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
One Lung Ventilation OLV, Esophageal Atresia
The Effect of Dexmedetomidine on Oxygen During One Lung Ventilation in Pediatric Surgery.
The children who will undergo OLV (one lung ventilation) through general anesthesia will be divided into two groups: The first will be intravenous infusion of dexmedetomidine at 0.4 mcg / kg / hour, and the second will be…
- Conditions
- One Lung Ventilation OLV, Esophageal Atresia, Hydrocystoma, Pneumonectomy
- Trial name
- RCT (NCT04932746)
- Testing
- Dexmedetomidine
- Where
- Syria
- Volunteers
- 110 people
- Sponsor
- Damascus University
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Metastatic Lung Cancer
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible.
- Trial name
- LIBERTYLUNG (NCT04790682)
- Testing
- assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Institut Curie
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Unsuspected Pulmonary Embolism
Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
The same initial and long-term anticoagulation is suggested for unsuspected pulmonary embolism as for patients with symptomatic embolism.
- Trial name
- NCT01727427
- Testing
- Heparin, fondaparinux, vitamin-K antagonists, aspirin
- Where
- 46 sites in United States, Austria and 6 more
- Volunteers
- 695 people
- Sponsor
- G. d'Annunzio University
Carcinoma, Non-small Cell Lung
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
This study will use imaging to look at tumor response to erlotinib (Part I) and the combination of erlotinib and dalotuzumab (Part II).
- Trial name
- NCT00729742
- Testing
- Comparator: erlotinib + dalotuzumab, Comparator: erlotinib monotherapy
- Volunteers
- 49 people
- Sponsor
- Merck Sharp & Dohme LLC
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.
- Conditions
- Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
- Trial name
- NCT05338970
- Testing
- Patritumab Deruxtecan, Platinum-based chemotherapy
- Where
- 182 sites in United States, Australia and 19 more
- Volunteers
- 586 people
- Sponsor
- Daiichi Sankyo
Lung Cancer
Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281970
- Testing
- cisplatin, docetaxel, adjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer-Associated Thrombosis (CAT)
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
- Trial name
- ROXI-CAT-I (NCT07410117)
- Testing
- REGN7508
- Where
- 23 sites in United States, Georgia and 1 more
- Volunteers
- 1,120 people
- Sponsor
- Regeneron Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Brain Metastases
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT06282874
- Testing
- Lorlatinib
- Where
- 3 sites in China
- Volunteers
- 41 people
- Sponsor
- Guangdong Association of Clinical Trials
Lung Neoplasms
TELESCOPE- TELEhealth Shared Decision-making COaching
Hypothesis 1a: The investigators anticipate that navigator decision coaching, compared to enhanced usual care (EUC) will result in higher quality SDM for lung cancer screening (LCS )(primary outcome), greater knowledge of lung…
- Trial name
- NCT05491213
- Testing
- TELESCOPE, Remote Decision Coaching with Navigation Intervention
- Where
- 2 sites in United States
- Volunteers
- 594 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Lung Cancer (NSCLC)
Navigation Bronchoscopy Guided Microwave Ablation Versus SBRT in Early NSCLC
Background: Stereotactic body radiotherapy (SBRT) is a standard definitive local therapy for medically inoperable early stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT07722182
- Testing
- Navigation Bronchoscopy-Guided Microwave Ablation, Stereotactic Body Radiotherapy (SBRT)
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Carcinoma, Non-small Cell Lung
Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer
This study will enroll elderly patients with advanced non-small cell lung cancer who are at high risk of developing chemotherapy toxicity (side effects).
- Trial name
- NCT02590003
- Testing
- Carboplatin, Nab-paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
SCLC, SCLC, Extensive Stage
Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
This is an open-label, single-arm, phase 2 study to evaluate the safety and efficacy of golidocitinib with PD-1 inhibitors as maintenance treatment in patients with previously untreated extensive-stage small cell lung cancer.
- Trial name
- JACKPOT38 (NCT07110103)
- Testing
- golidocitinib with PD-1 inhibitors
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer
Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Primary Objective: To determine the clinical sensitivity and specificity of the Biomoda CyPath™ Early Lung Cancer Detection Assay using sputum specimens from two cohorts of participants and estimate the required sample size to…
- Trial name
- NCT00894127
- Testing
- CyPath
- Where
- 3 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Biomoda Inc.
Non-small Cell Lung Cancer
Endobronchial Ultrasound vs Mediastinoscopy in NSCLC
Proper staging of Lung cancer is of paramount concern when determining a treatment regime. Currently the assessment of surgical candidacy is performed with the staging process, mainly the mediastinoscopy.
- Trial name
- NCT00372203
- Testing
- Endobronchial Ultrasound Guided Transthoracic Needle Biopsy
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without…
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00003313
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- 264 sites in United States, Canada
- Volunteers
- 243 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Neoplasm
Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry
Therapeutic algorithms for lung cancer are mainly based on randomised controlled trials which excluded patients with severe co-morbidities.
- Trial name
- NCT03368820
- Testing
- No intervention
- Where
- 6 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- European Lung Cancer Working Party
Lung Cancer
Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004159
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Alabama at Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.